Mini-Review: The Complete Guide to Gut Peptides That Control How Full You Feel | Research

The takeaway

The gastrointestinal tract and pancreas release at least 8 hormones regulating satiety and body weight, with GLP-1, PYY, and amylin showing the most therapeutic promise for obesity treatment.

GLP-1 predicted
This 2004 review identified GLP-1 as having the most therapeutic promise for obesity — validated over a decade later by semaglutide's blockbuster success

What the researchers found

At least 8 gut/pancreatic hormones regulate satiety, with GLP-1, PYY, and amylin identified as the most promising therapeutic targets for obesity — with combination therapy suggested for superior outcomes.

Why it matters

This review identified GLP-1 as a top therapeutic target years before semaglutide's success. It also predicted combination peptide therapy — validated by tirzepatide (GLP-1/GIP dual agonist).

How the study worked

Mini-review of gut peptide satiety regulation covering ghrelin, GLP-1, oxyntomodulin, PYY, CCK, amylin, PP, and bombesin/GRP.

What this study cannot tell us

Brief review from 2004. The therapeutic hierarchy has shifted since (GLP-1 became dominant). Combination therapy details were speculative.

How to read the evidence

Moderate evidence from a concise review synthesizing the gut peptide satiety landscape.

When this study was published

Published in 2004. This review's prediction that GLP-1 would be the top obesity target was dramatically validated by semaglutide/tirzepatide.

The bigger picture

The gut is the body's largest endocrine organ for appetite control. This review mapped the complete satiety peptide landscape that modern obesity drugs now target.

Questions still open

Will triple-peptide combinations outperform dual agonists?
Which combination of satiety signals produces the best weight loss with fewest side effects?
Can the gut peptide profile predict which obesity drug will work best for each patient?

Common questions

How many hormones control appetite?

At least 8 from the gut and pancreas alone, plus brain peptides. Ghrelin makes you hungry; GLP-1, PYY, CCK, and others make you full. It's a remarkably complex system.

Did this review predict Ozempic?

In a sense, yes — it identified GLP-1 as having the most therapeutic promise for obesity in 2004, more than 15 years before semaglutide (Ozempic/Wegovy) became one of the most impactful drugs in medicine.

Read the original research

Minireview: Gut peptides regulating satiety.

Endocrinology, 145(6), 2660-5

View on PubMed ↗

Citation

Druce, Maralyn R; Small, Caroline J; Bloom, Stephen R. (2004). Minireview: Gut peptides regulating satiety.. Endocrinology, 145(6), 2660-5.